

Index

Aarskog-Scott syndrome 120–1	maternal source 45, 49–50, 53	AZFa 99, 121
abortion, spontaneous 52–3, 65–6	paternal source 49, 53	AZFb 99–100, 121
recurrent 148–9	PGD/PGS 167–8, 192–3	AZFc 100, 121
abortion, therapeutic 135	<i>see also specific syndromes</i>	gr/gr deletions 100, 121
aCGH (array CGH) 20–3, 65, 167–8	Angelman syndrome 78, 174–5, 175	
ADAR family (RNA editases) 88	anti-Müllerian hormone (AMH) 118, 147	babies, newborn screening 132, 133
ADO (allelic drop-out) 17, 25, 163, 164	APOBEC family (RNA editases) 88–9	BAC arrays (bacterial artificial chromosomes) 20–2
adoption 134	apoptosis 63	base pairing 1
adrenal gland, CAH 114–15	Argonaute proteins 89	Beckwith–Weidemann syndrome 78, 121, 175, 175–6
adult-onset diseases 131, 133–5, 138–9	array CGH (aCGH) 20–3, 65, 167–8	bereavement 136–7
PGD 164–5, 189–90	Ashkenazi Jews 154, 195	blastocysts
Affymetrix SNP-arrays 24–5	assisted reproductive technologies (ART)	effect of mosaicism on embryonic development 62–3
age effects	chromosomal abnormalities	PGD/PGS 62, 160
maternal 49–50, 53	parental 147, 149–50	<i>see also</i> preimplantation embryos
paternal 46, 49	postimplantation 64–5	blastomeres, biopsy 159–60
alleles 4	preimplantation embryos 52–4, 61–2	blepharophimosis, ptosis, epicanthus inversus syndrome (BPES type 1) 117
allelic drop-out (ADO) 17, 25, 163, 164	epigenetics 173–4, 174, 182	BMP15 gene (bone morphogenetic protein 15) 106, 117
Alu retrotransposons 87, 89, 93	effect on the children 78, 174–6, 180, 181	BRCA1/BRCA2 genes 131, 139, 189–90
amenorrhea 113–17	effect on the embryo 177, 182	BUB1 kinase 58
<i>see also</i> female infertility	effect on the oocyte 176–7, 182	
AMH (anti-Müllerian hormone) 118, 147	effect on placental tissue and cord blood 177–80, 182	CAH (congenital adrenal hyperplasia) 114–15
amniocentesis 64, 136	ethics <i>see</i> ethics	candidate gene method (reverse genetics) 124
anaphase	gamete donation 139–42, 152–3, 184–8	carrier testing 131–3, 154
meiosis 42, 45–6	genetic testing 110, 151	ethics 134, 194–6
mitosis 5, 54	ICSI 97, 103, 122–3, 149–50, 152, 174–5	of gamete donors 141, 186–8
anaphase lagging 54	indications for 97, 127, 139–40	cascade screening 133
anaphase-promoting complex (APC/C ^{cdc20}) 45–6	recurrent implantation failure 49, 149	CDK1 (cyclin-dependent kinase 1) 45–6
androgen deficiency 114, 118–19	asthenozoospermia 119–20, 121	cDNA (complementary DNA) 9–10
androgen excess 114–15	AURKC gene 122	<i>see also</i> retrotransposons
androgen insensitivity 114, 119	Aurora B/Aurora C proteins 58	cell cycle 4–5, 45–6
androgen receptor gene mutations 114	autonomy 134	<i>see also</i> meiosis
androgenetic embryos 68	in carrier screening 195	cell-free fetal DNA testing 136
aneuploidy 12, 18–23	in PGD/PGS 191–2, 194	CENP-A histone 59
detection 7, 167–8	autosomal dominant diseases 13	centrioles 43
incidence 49, 52–3	autosomal recessive diseases 12	centromeres 7, 43, 45
infertility	azoospermia <i>see</i> male infertility	epigenetic markers 59–61
female 104–6	azoospermia factor (AZF) region	
male 97–8	microdeletions 98, 110, 151–2	
meiotic errors 49–50, 52–4		
chromosomal segregation errors 42–3, 54		
environmental causes 50		

Index

- centrosomes 43, 45, 55–7
 CGH (comparative genomic hybridization)
 array CGH 20–3, 65, 167–8
 metaphase CGH 18–20, 167
 chemical factors affecting gametes 50, 94, 125
 chiasmata 33, 36, 40, 42
 children
 conceived using donated gametes 141–2, 185–6
 epigenetic effects of ART 78, 174–6, 180–1
 genetic testing 134
 health effects of PGD 169
 newborn screening 132–3
 of parents with genetic conditions 139, 142, 189
 chimeric DNA artefacts in WGA 17
 chorionic villus sampling (CVS) 63–5, 136
 chromatin 3, 58–61
 imprinting and 73, 77–8
 chromosomal abnormalities 11–12
 detection methods
 CGH 18–23, 27, 65, 167–8
 FISH 7, 110, 157, 166–7
 karyotyping 7, 64
 infertility
 female 104–10, 147–9, 151
 male 97–104, 110, 149–50
 in IVF embryos 52–4, 61–2, 64–5
 meiotic errors 42–3, 47–50, 52–4, 168
 mitotic errors 54
 mosaicism 66
 effect on development 62–3
 in IVF embryos 53–4, 61–2, 64–5
 in preimplantation embryos 53–4, 62–3
 in prenatal diagnosis 63–5
 in spontaneous abortion 65–6
 in Turner syndrome 105
 in patients undergoing ART 147, 149–50
 PGD/PGS 166–9, 192–3
 see also aneuploidy; translocations
 chromosomal behavior during meiosis 33–45
 chromosomal passenger complex (CPC) 57–8, 60–1
 cleavage stage embryos
 biopsy 159–60
 chromosomal mosaicism 53–4, 63
 mitosis 55–61
 codons 6
 cohesion proteins 40, 42–3, 46, 50
 communication
 in genetic counseling 128, 132, 138
 telling children they were conceived using donated gametes 141, 142, 185–6
 comparative genomic hybridization (CGH)
 array CGH 20–3, 65, 167–8
 metaphase CGH 18–20, 167
 complete androgen insensitivity 114
 complex chromosome rearrangements 103
 confidentiality 138
 confined placental mosaicism 64
 congenital adrenal hyperplasia (CAH) 114–15
 congenital bilateral absence of the vas deferens (CBAVD) 119, 150–1
 Congenital Disabilities Act (1976) (UK) 141
 congression 43, 45
 copy number variation 18–24, 109, 167–8
 see also trinucleotide repeat diseases
 counseling *see* genetic counseling
 CPC (chromosomal passenger complex) 57–8, 60–1
 CpG dinucleotides, methylation 75, 172
 crossover of chromosomes 33, 38–42
 cryopreservation
 embryos 160
 oocytes 176
 cryptorchidism 93–4
CTFR gene (cystic fibrosis gene) 119, 150–1
 culture medium used for preimplantation embryos 177
 cyclin-dependent kinase 1 (CDK1) 45–6
CYP21A2 mutations in CAH 114–15
 cystic fibrosis (CF) 119, 150–1
 cytogenetics
 FISH 7, 110, 157, 166–7
 karyotyping *see* karyotyping
 cytokinesis 54
 cytosine, methylation 75, 172
 cytotrophoblast 63–4
DAX1 (*NR0B1*) gene 108, 119
DAZ genes 100
Dazl protein 35
DBY gene deletion 99
 deafness, selection for in PGD 191–2
 decision-making in genetic counseling 128, 135
 in PGS 194–5
 deletions 23
 Y chromosome microdeletions 98, 110, 121, 151–2
 demethylation of DNA 78–81, 173
 Developmental Origin of Health and Disease (DOHaD) paradigm 174, 181–2
DIAPH2 gene 106
 DICER protein 89
 dideoxynucleotides 8–9
 differentially methylated domains (DMDs) 70, 75–6
 de novo methylation in gametes 71–4, 78, 92, 173
 erasure of methylation in PGCs 80–1, 173
 maintenance of methylation 74–5, 78–80, 177
 transcriptional suppression 76–7
 direct to consumer (DTC) genetic testing 132–3
 disorders of sexual development or differentiation (DSD) 113–15
 androgen insensitivity 114, 119
 CAH 114–15
 isolated GnRH deficiency 115–16, 119
 Kallmann syndrome 115, 119, 154
 Klinefelter syndrome (47,XXY) 97–8, 109, 150
 Swyer syndrome (46,XY females) 107–9, 114
 TDSD (46,XX males) 100–2, 118
 trisomy X 105–6
 Turner syndrome (45,X) 104–5, 109–10, 147
 DMDs *see* differentially methylated domains
 DNA
 demethylation 78–81, 173
 genetic code 6
 methylation *see* methylation of DNA
 mitochondrial 3
 replication 4
 sequencing 8–9, 11, 26–9, 124
 structure 1–3
 DNA polymerases (Taq) 8, 16, 163–4
 DNA repair enzymes 89
 DNA transposons 83
 see also retrotransposons
 DNMT enzymes (DNA cytosine methyltransferases) 88
 DNMT1/*Dnmt1* 74–5, 78–80
 DNMT3A (*de novo* DNA methyltransferase) 71, 90
 DNMT3L (DNMT3A auxiliary factor) 71–4, 78
 donation of gametes 139–42

Index

- ethics 140–2, 184–8
 telling the children 141–2, 185–6
 genetic testing 141, 151–3, 186–8
 double strand breaks 38, 40
 Down syndrome (trisomy 21) 49, 104
DPY19L2 gene 122
 DSD *see* disorders of sexual
 development or differentiation
 Duchenne muscular dystrophy 131–3
 duplications 23, 102, 108
 dynamic mutations 13
 dystrophia myotonica type 1
 (DM1) 13, 120, 137
- eggs *see* oocytes
 embryonic genome activation
 (EGA) 56
 endocrine disrupting chemicals 50,
 94, 125
 endogenous small interfering RNA
 (endo-siRNA) 89
 environmental factors
 affecting gametes 50, 94, 125
 epigenetic changes during
 pregnancy 174
 epigenetics 68–81, 172–4
 and ART 173–4, 174, 182
 effect on the children 78, 174–6,
 180–1
 effect on the embryo 177, 182
 effect on the oocyte 176–7, 182
 effect on the placental tissue and
 cord blood 177–80, 182
 parental subfertility as source of
 abnormalities 180–1
 DMD features 75–6
 DNA methylation 69–71
 acquisition 47, 71–4, 78, 92, 173
 erasure in PGCs 69, 71, 80–1, 173
 maintenance 74–5, 78–80, 177
 in the early embryo 61, 78–80,
 173–4, 177, 181–2
 environmental influences 174
 histone modification 58–60, 73,
 77–8
 imprinting disorders 78, 121, 174–6
 imprinting in the mouse 68–9
 milestones 68
 monoallelic expression 76–7
 retrotransposon transcriptional
 control 88, 90–2
- ethics
 gamete donation 140, 142, 184–5
 genetic testing 141, 186–8
 telling the children 141–2, 185–6
 genetic testing
 of children 134
 for HD 164–5, 189
 for HLA-typing 165, 191
- PGD 157, 188–92
 PGS 192–4
 sharing results with other family
 members 128, 138
 source of biopsied cells 159–60,
 192
 potential parents who have genetic
 conditions 139, 142, 189
 prenatal diagnosis 192–3
 ethnicity, carrier screening 133, 154,
 186, 195
 European Cell and Tissue
 Directives 152
 exclusion testing in PGD 164, 189
 exome sequencing 11, 28–9, 124
 exons 3–4
- facio-digito-genital syndrome
 120–1
- families
 cascade screening 133
 sharing a genetic diagnosis
 with 128, 138
 family history 129
 female age 49–50, 53
 female infertility
 androgen insensitivity/
 excess 114–15, 119
 chromosomal abnormalities 147–9
 autosomal 107
 monosomy X (Turner
 syndrome) 104–5, 109–10, 147
 trisomy X 105–6
 X chromosome structural
 abnormalities 106–7, 110–11
 XY gonadal dysgenesis (Swyer
 syndrome) 107–9, 114
 fragile X premutations 106, 111,
 116–17, 151
 genetic testing 111, 147–9, 151, 154
 GnRH deficiency 115–16
 POF/POI 105, 106–7, 116–17,
 147–8
 recurrent implantation failure 49,
 149
 recurrent miscarriage 148–9
 fertilization 45
 fetal blood sampling 136
 5-alpha reductase deficiency 118
 fluorescent in situ hybridization
 (FISH) 7, 110, 157, 166–7
FMRI gene
 ethical implications of testing
 gamete donors for the
 premutation 187–8
 female carriers of premutation
 alleles 106, 111, 116–17, 151
 folliculogenesis 46, 61
- forward genetics (positional
 cloning) 124
 fragile X syndrome 13, 116, 151
 ethical implications of testing
 gamete donors for the
 premutation 187–8
 FMRI premutation alleles 106, 111,
 116–17, 151
 PGD 164
 frameshift mutations 13
- G-banding 7
 galactosemia 117
 gamete donation 139–42
 ethics 140–2, 184–8
 telling the children 141–2,
 185–6
 genetic testing 141, 151–3, 186–8
 gametes *see* oocytes; spermatozoa
 gametogenesis
 environmental chemicals
 affecting 50, 94, 125
 imprinting 71–4, 78, 92, 173–4
 effect of ART on the
 oocyte 176–7, 182
 errors associated with
 oligospermia 180–1
 iPS-derived 94
 meiosis *see* meiosis
 retrotransposons and 71, 89–94
 sexual dimorphism 37, 46–7,
 49–50
 GCOS-24 score 129
 GeneChip Human Mapping 250K NspI
 Array (Affymetrix) 24–5
 genes 3–4
 genetic code 6
 genetic counseling 128–32
 carrier screening 195
 DTC tests 133
 fertility/infertility 111, 117
 of gamete donors 141
 grief and guilt 135–9
 implications of future parental
 ill-health 139, 142
 late-onset disorders 131, 138–9
 prior to PGD 136
 prior to prenatal diagnosis 135–6
 reproductive choice 134–6
 uncertainty 132, 135, 139
 and the wider family 128, 138
 in X-linked disorders 114, 117
 genetic testing
 for carrier status 131–4, 154, 188,
 194–6
 in children 134
 diagnosis 131, 133–4
 ethics *see* ethics, genetic testing
 gamete donors 141, 151–3, 186–8

Index

- genetic testing (*cont.*)
 in infertile patients 109–11, 122–3, 146–54
 females 111, 147–9, 151, 154
 males 149–52, 154
 preimplantation *see* preimplantation
 genetic diagnosis,
 preimplantation genetic
 screening
 prenatal diagnosis 136
 presymptomatic testing 133–4, 138–9
 public health screening
 programs 132–3, 195
 sharing results with other family
 members 128, 138
 GenomePlex (Sigma-Aldrich) 25
 GenomiPhi (GE Healthcare) 25
 germ cells *see* primordial germ cells
 globozoospermia 122
 gonadal dysgenesis
 46,XX males 100–2, 118
 46,XY females 107–9, 114
 Turner syndrome (45,X) 104–5,
 109–10, 147
 gonadotropin-releasing hormone
 (GnRH) deficiency 115–16,
 119
 grief 136–7
 guilt 133, 137–9
 gynogenetic embryos 68

H19/Igf2/H19/IGF2 imprinted
 genes 74–6, 78
 H19 abnormalities in ART
 176–8
 haplotype analysis 29–30
 HD *see* Huntington disease
 hemophilia 191
 hermaphroditism (true
 hermaphrodites) 114, 118
 HERVs (human endogenous
 retroviruses, LTRs) 84–5
 heterochromatin protein 1
 (HP1) 59–60
 high-throughput sequencing *see* whole
 genome sequencing
 histocompatibility selection using
 PGD 161, 165–6, 191
 histones 3
 epigenetics 58–60, 73, 77–8
 retrotransposon control 88
 history-taking in genetic
 counseling 129, 137
 HLA (human leukocyte antigen)
 typing in PGD 161, 165–6, 191
 homozygosity mapping 124
 Human Fertilisation and Embryology
 Acts (1990, 2008) (UK) 140–1
 Huntington disease (HD) 133–5
 PGD 164–5, 189
 hypogonadotropic hypogonadism 154
 female 115–16
 male 119
 ICSI (intracytoplasmic sperm
 injection) 97, 103, 122–3,
 149–50, 152
 imprinting disorders 174–5
Igf2/H19/H19/IGF2 imprinted
 genes 74–6, 78
 Illumina HiSeq2000 sequencing
 system 26
 Illumina SNP-arrays 25–6
 immotile cilia syndrome 119–20
 implantation, recurrent failure 49, 149
 imprinting 68–81, 173–4
 ART and 174
 effect on the children 78, 174–6,
 180
 effect on the embryo 177, 182
 effect on the oocyte 176–7, 182
 effect on the placenta and cord
 blood 177–80, 182
 parental subfertility as source of
 abnormalities 180–1
 chromatin modification 73, 77–8
 disorders 78, 174–6
 DMD features 75–6
 DNA methylation 69–71
 acquisition 47, 71–4, 78, 92, 173
 erasure in PGCs 69, 71, 80–1, 173
 maintenance 74–5, 78–80, 177
 in the early embryo 61, 78–80,
 173–4, 177, 181–2
 milestones 68
 monoallelic expression 76–7
 in the mouse 68–9
 imprinting control element (ICE) 75
in vitro fertilization (IVF)
 chromosomal abnormalities
 parental 147, 149–50
 postimplantation 64–5
 preimplantation embryos 52–4,
 61–2
 epigenetics 173–4, 174, 182
 effect on the children 78, 174–6,
 180–1
 effect on the embryo 177, 182
 effect on the oocyte 176–7, 182
 effect on placental tissue and cord
 blood 177–80, 182
 parental subfertility as source of
 abnormalities 180–1
 genetic testing 110, 151
 recurrent implantation failure 49,
 149
in vitro maturation (IVM) 176
 INCENP subunit of the CPC 60
 incontinentia pigmenti 13
 induced pluripotent cells (iPS) 94
 infertility 113–25
 causes *see* female infertility, male
 infertility
 clinical examination 122
 genetic testing 109–11, 122–3,
 146–54
 research into new genetic
 diseases 109, 123–4
 interchromosomal effect 168
 interphase 4–5, 46
 intracytoplasmic sperm injection
 (ICSI) 97, 103, 122–3, 149–50,
 152
 imprinting disorders 174–5
 introns 3–4
 inversion 47–9, 102–3, 166
 detection 28
 isolated gonadotropin-releasing
 hormone deficiency (IGD)
 females 115–16
 males 119
 IVF *see in vitro* fertilization
 IVM (*in vitro* maturation) 176

 Jewish (Ashkenazi) ethnicity 154,
 195
 jumping genes *see* retrotransposons

KAL1 gene 115
 Kallmann syndrome 115, 119, 154
 Kartagener syndrome 119–20
 karyomapping 29–30, 170
 karyotyping 7, 154
 in female infertility 148–9
 limitations 64
 in male infertility 150
 normal karyotype 1–3
Kcnq1/KCNQ1 gene 76–8, 176, 177
 Kennedy disease 120
 Klinefelter syndrome (47,XXY) 12,
 97–8, 109, 150

 L1 elements (LINEs) 85–7, 93, 94
 control mechanisms 87–9
 late-onset disorders 131, 133–5, 138–9
 PGD 164–5, 189–90
 legal issues
 confidentiality 138
 gamete donation and
 surrogacy 140–1, 152–3, 185
 PGD 159, 192
 LH pre-ovulatory surge 45, 46
 LH receptor mutations 114, 118
 LINEs (long interspersed
 elements) 85–7, 93, 94
 control mechanisms 87–9

Index

- linkage analysis 161
 loss-of-heterozygosity (LOH) 23
 Lsh (lymphoid specific helicase) 88
 LTRs (long terminal repeats, HERVs) 84–5
 luteinizing hormone (LH)
 pre-ovulatory surge 45, 46
 receptor mutations 114, 118
- macrocephalia (spermatic) 122
 male age 46, 49
 male infertility 97
 asthenozoospermia 119–21
 chromosomal abnormalities 149–50
 46,XX males 100–2, 118
 47,XXY and variants (Klinefelter syndrome) 97–8, 109, 150
 47,YYY 98
 balanced chromosomal rearrangements 102–4, 149
 Y chromosome
 microdeletions 98, 110, 121, 151–2
 genetic testing 149–52, 154
 GnRH deficiency 119
 imprinting errors in
 spermatozoa 180–1
 mitochondrial diseases 121
 retrotransposons 71, 89–94
 synaptic failure 47
 syndromic diseases 119–21, 150–1
 teratozoospermia 122
- maternal age 49–50, 53
 maternal control of early
 embryogenesis 45, 56
 maternal imprinting 68–9, 71, 74–5
 Angelman syndrome 78, 174–5, 175
 MDA (multiple displacement
 amplification) 15–17, 20, 25, 164
- meiosis 5, 35–46
 cell cycle regulation 45–6
 chromosome cohesion 40, 42–3, 46, 50
 errors 42–3, 47–50, 52–4, 168
 inversion 47–9, 102–3, 166
 see also aneuploidy;
 translocations
 initiation 35
 recombination 33, 38–42, 47
 sexual dimorphism 37, 46–7, 49–50
 meiotic arrest during
 oogenesis 35–6, 45
 spindle formation and chromosome segregation 33–4, 42–5
 synapsis 35–8, 47
- men
 age 46, 49
 infertility *see* male infertility
- MEST* gene 176–7
 metaphase
 meiosis 45–6
 mitosis 5
 metaphase CGH (mCGH) 18–20, 167
 methylation of DNA 69–71, 172
 acquisition (*de novo*
 methylation) 71–4, 78, 92, 173
 and chromatin modification 73, 77–8
 maintenance 74–5, 78–80, 177
 transcriptional control
 of imprinted genes 76–7
 of retrotransposons 88, 90–2
 see also demethylation of DNA
 methylation of histones 59, 88
 microarray analysis 10, 109
 aCGH 20–3, 65, 167–8
 compared with genome sequencing 28
 SNP-arrays 10, 23–6, 65, 170
 microRNA (miRNA) 5, 89
 microsatellite repeats (short tandem repeats), in PGD 161–4
 microtubule organizing centers (MTOC) (centrosomes) 43, 45, 55–7
 mild androgen insensitivity 114, 119
- Mili protein (PIWIL2) 90
 miscarriage 52–3, 65–6
 recurrent 148–9
 missense mutations 13
 mitochondrial diseases 121
 PGD 161, 165, 190
 mitochondrial DNA 3
 mitosis 5, 37
 differences between the early
 embryo and adult cells 55–61
 errors 46, 54
 Miwi protein (PIWIL1) 91–2
 Miwi2 protein (PIWIL4) 90
 mobile DNA elements *see*
 retrotransposons
- monogenic diseases 12–13, 154
 female infertility 106–7, 113–17, 148, 151, 154
 male infertility 117–22, 150–1, 154
 PGD 160–6, 168, 189–90
 monosomy 12, 49
 Turner syndrome (monosomy X) 104–5, 109–10, 147
 morula *see* cleavage stage embryos
 mosaicism *see* chromosomal abnormalities, mosaicism
 multiple displacement amplification (MDA) 15–17, 20, 25, 164
- muscular dystrophy 131–3
 mutation types 13
 myotonic dystrophy type 1 (DM1) 13, 120, 137
- neurofibromatosis type 1 (NF1) 135
 newborn screening 132–3
 next generation sequencing (NGS) *see*
 whole genome sequencing
 non-coding RNA (ncRNA) 5, 89
 transcriptional suppression 76–7, 90–2
 non-disclosure PGD 164–5
 nondisjunction 12, 54
 nonsense mutations 13
 Noonan syndrome 120
NR0B1 (*DAX1*) gene 108, 119
NR5A1 gene 117
 nucleotides 1
- oligonucleotide arrays 22
 oligo(zoo)spermia 102, 149
 imprinting errors 180–1
 see also male infertility
- oocytes
 cryopreservation 176
 donation 152–3, 187
 see also ethics, gamete donation
 effect of ART on imprinting 176–7, 182
 PB biopsy 159, 192
- oogenesis 35, 46
 folliculogenesis 46, 61
 imprinting 74, 78, 173
 compared with
 spermatogenesis 47, 71, 74
 effect of ART 176–7, 182
 maternal age effects 49–50, 53
 meiosis 37
 arrest 35–6, 45
 cell cycle regulation 45–6
 errors 47, 53
 initiation 35
 progression 45
 X chromosome behavior 42, 47
 see also meiosis
 mRNA and protein stores 45, 56
 recombination 33, 40, 42
- ovarian reserve, estimation 147
 ovarian stimulation
 effect on imprinting 176–7, 182
 effect on oocyte quality 61–2, 192
 ovulation 46
- pachytene piRNA 91–2
 paired-end DNA sequencing 17, 26, 28
 parental support algorithm 26
 partial androgen insensitivity 114, 119
 paternal age 46, 49

Index

- paternal imprinting 61, 68–9, 71, 74, 75, 173
 abnormalities 78
 paternal origin of zygotic centrosome 56–7
 PCR (polymerase chain reaction) 7–8
 in PGD 162–5, 167
 Q-RT-PCR 9–10
 in whole-genome amplification 16, 25, 163–4
 PCS (preconception carrier screening) 131–3, 154
 ethics 134, 194–6
 pediatrics *see* children
 persistent Müllerian duct syndrome 118
 PGCs (primordial germ cells) 69, 71, 80–1, 89–90, 173
 PGD *see* preimplantation genetic diagnosis
 PGS *see* preimplantation genetic screening
 PIWI-interacting RNA (piRNA) 89, 90–2
 PIWIL/PIWIL proteins/genes 89–93
 placenta
 confined placental mosaicism 64
 epigenetics in ART babies 177–80, 182
 HERVs and 85
 polar bodies (PB) 45
 biopsy 159, 192
 polymerase chain reaction *see* PCR
 positional cloning (forward genetics) 124
 post-transcriptional control of retrotransposons 88–92
 post-transcriptional processing of mRNA 5
 Prader–Willi syndrome 78, 176
 precocious separation of sister chromatids 42–3, 49
 preconception carrier screening (PCS) 131–3, 154
 ethics 134, 194–6
 predictive testing 133–4, 138–9
 in children 134
 preimplantation embryos
 aneuploidy (meiotic errors) 52–4
 chromosomal mosaicism (post-meiotic errors) 52–4, 66
 effect on embryonic development 62–3
 in IVF embryos 53–4, 61–2
 culture medium for IVF embryos 177
 differences in mitotic mechanisms when compared with adult cells 55–61
 epigenetics
 effect of ARTs on 177, 182
 environmental effects 174
 maintenance of DNA methylation 74–5, 78–80, 177
 paternal chromatin 61
 reprogramming 78–80, 173–4
 preimplantation genetic diagnosis (PGD) 157–70
 analytical techniques 157–8, 161–2
 aCGH 167–8
 CGH 167
 FISH 157, 166–7
 PCR 162–5, 167
 WGA 29–30, 163–4, 167–8
 biopsy 159–60, 192
 for chromosomal abnormalities 166–9
 cryopreservation of embryos 160
 ethics 157, 159, 160, 164–5, 188–92
 genetic counseling 136
 indications 160–1, 166
 legal issues 159, 192
 misdiagnosis 169
 for monogenic conditions 160–6, 168
 BRCA1/BRCA2 189–90
 HD 164–5, 189
 HLA-typing and selection 161, 165–6, 191
 mitochondrial diseases 161, 165, 190
 X-linked disorders 164, 165, 191
 outcomes 168–9
 quality assurance 169
 research areas 29–30, 169–70
 preimplantation genetic screening (PGS)
 effect of mosaicism 62
 ethics 192–4
 premature ovarian failure/insufficiency (POF/POI) 116–17
 fragile X premutations 106, 111, 116–17, 151
 X chromosome abnormalities 105, 106–7, 147–8
 prenatal diagnosis
 chromosomal mosaicism 63–5
 counseling and support 135–6
 ethics 192–3
 timing 129
 presymptomatic testing 133–4, 138–9
 in children 134
 primary ciliary dyskinesia 119–20
 primordial germ cells (PGCs) 69, 71, 80–1, 89–90, 173
 prometaphase
 meiosis 42
 in oocytes 45–6
 in spermatocytes 43–5
 mitosis 5
 promoter sequences 4, 75
 prophase
 meiosis 33, 35–8
 mitosis 5
 prospermatogonia 90–2
 protein synthesis (translation) 6–7
 Q-RT-PCR (quantitative real time PCR) 9–10
 quality assurance, in PGD 169
 REC8 (cohesin protein) 46
 recombination 33–4, 38–42, 47
 see also translocations
 recombination nodules 38
 referral for genetic counseling/testing 129, 133
 REPLI-g (QIAGEN) 25
 retinitis pigmentosa 133
 retinoblastoma 176
 retinoic acid 35
 retrotransposons 83–4
 association with disease 86–7, 89
 control mechanisms 87–92
 in iPS-derived gametes 94
 LINEs 85–7, 93–4
 LTRs (HERVs) 84–5
 SINEs 87, 93
 spermatogenesis and 71, 89–94
 SVA elements 87
 reverse genetics 124
 reverse transcription 85–6
 ribosomes 6–7
 risk, patient understanding of 132
 RNA 5
 non-coding 5, 89
 transcriptional suppression 76–7, 90–2
 translation 6–7
 RNA editing 88–9
 RNA interference (RNAi) 89
 RNA-Induced Silencing Complex (RISC) 89
 Robertsonian translocations 12, 47, 166
 infertility 103–4, 149
 PGD 166, 169
 Roche 454 sequencing system 26
 RSPO1 gene (R-spondin 1) 102, 114
 S phase 4
 SAC (spindle assembly checkpoint) 43, 45, 57–8
 Sanger sequencing of DNA 8–9

Index

- screening
 of gamete donors 141, 151–3,
 186–8
 PCS 131–4, 154, 194–6
 PGS 62, 192–4
 public health programs 132–3,
 195
 Sertoli-cell-only syndrome 99
 sex chromosomes *see* X chromosome,
 Y chromosome
 sex selection 191
 short interspersed elements
 (SINEs) 87, 93
 short tandem repeats (STRs)
 161–4
 Silver–Russell syndrome 176
 single-cell genomics 15–31
 aCGH 20–3, 65, 167–8
 amplification (WGA) 15–18, 25,
 163–4, 167–8
 mCGH 18–20, 167
 in PGD 29–30, 164, 170
 sequencing 26–9
 SNP arrays 23–6, 170
 situs inversus 119–20
 small interfering RNAs (siRNA)
 89
 SNP arrays 10, 23–6, 65, 170
 SNPs (single nucleotide
 polymorphisms) 23, 27–9
SNRPN/Snrpn gene
 imprinting 176–80
 Angelman syndrome 174–5
 SOLiD sequencing system (Life
 Technologies) 26
 SOX3 gene 102
 SOX9 gene 101–2
 sperm donation 139–42, 151–3,
 187–8
 see also ethics, gamete donation
 spermatogenesis
 environmental chemicals
 affecting 50, 94, 125
 imprinting 71–4, 78, 92, 173
 compared with oogenesis 47, 71,
 74
 errors associated with
 oligospermia 180–1
 meiosis 37, 43–7
 aneuploidy 49, 50, 53
 cell cycle regulation 45–6
 initiation 35
 pachytene piRNAs 91–2
 sex chromosome
 segregation 35–6, 42
 see also meiosis
 paternal age effects 46, 49
 retrotransposons and 71,
 89–94
 spermatozoa, origin of zygotic
 centrosome 56–7
 spinal and bulbar muscular atrophy
 (Kennedy disease) 120
 spindle assembly checkpoint
 (SAC) 43, 45, 57–8
 spindle formation
 meiosis 42–5
 mitosis 5, 55–6
 zygotic centrosome is of paternal
 origin 56–7
 spinocerebellar ataxia type 1
 (SCA1) 133–4
 spontaneous abortion 52–3,
 65–6
 recurrent 148–9
 SRY gene
 in 46,XX males 100–1, 118
 in 46,XY females 108, 114
 Steinert's disease (DM1) 13, 120,
 137
 STELLA protein 79
 steroid hormone-related causes of
 infertility
 female 114–15
 male 118–19
 Stra8 protein 35
 STRs (short tandem repeats) 161–4
 superovulation *see* ovarian stimulation
 surrogacy 140, 142
 survivor guilt 139
 SVA (SINE-R/VNTR/Alu)
 elements 87
 Swyer syndrome (46,XY
 females) 107–9, 114
 synapsis 35–8, 47
 syncytin proteins 85
 Ta elements
 (L1PA1 retrotransposons)
 86
 Taq DNA polymerases 8, 16,
 163–4
 target primed reverse
 transcription 85–6
 telophase 5
 teratozoospermia 122
 termination of pregnancy 135
 testicular disorder of sex development
 (TDSD, XX male
 syndrome) 100–2, 118
 TET dioxygenases 79
 tetraploidy 11
 Tip60-p400 chromatin remodeling
 complex 78
 transcription 5
 retrotransposons 88, 90–2
 suppression in imprinted
 genes 76–8
 transgenerational epigenetic
 inheritance 181
 translation 6–7
 translocations 12, 166
 causing female infertility 147
 causing male infertility 100–1,
 149
 detection 28, 166–8
 PGD 158, 162, 166–9
 Robertsonian 12, 47, 103–4, 166,
 169
 transposons *see* retrotransposons
 trinucleotide repeat diseases 13,
 164–5
 DM1 13, 120, 137
 fragile X syndrome 13, 116, 151,
 164
 Huntington disease 133–5, 164–5,
 189
 Kennedy disease 120
 triploidy 11
 trisomy 12, 52–3
 confined placental mosaicism 64
 maternal age and 49–50
 trisomy 21 (Down syndrome) 49,
 104
 trisomy X 12, 105–6
 tRNA 6–7
 Turner syndrome (45,X) 104–5,
 109–10, 147
UBE3A gene in Angelman
 syndrome 78, 174–5
 umbilical cord blood, epigenetics 177,
 180
 uniparental disomy (UPD) 23, 64,
 69
 United States of America, genetic
 testing 134, 152–3
USP9Y deletion 99
 vas deferens, absent 119, 150–1
 virilization, in CAH 115
 vitrification of oocytes 176
 whole genome amplification
 (WGA) 163–4
 amplification methods 15–18, 25,
 163–4
 artefacts (and solutions) 17–18, 20,
 22–3, 25, 28
 in PGD 29–30, 164, 167–8
 whole genome sequencing 11,
 26–9
 exome sequencing 11, 28–9,
 124
 in PGD 29–30, 164, 170
 in PGS 193–4
 screening of gamete donors 186–8

Index

women	male infertility	Y chromosome
age 49–50, 53	46,XX males (XX male	abnormalities
infertility <i>see</i> female infertility	syndrome) 100–2, 118	46,XY females 107–9, 114
X chromosome	47,XXY (Klinefelter	47,XYY males 12, 98
female infertility 147–8	syndrome) 97–8, 109,	microdeletions 98, 110, 121,
structural abnormalities 106–7,	150	151–2
110–11	in meiosis 35–6, 42, 47	in meiosis 35–6, 42, 47
trisomy X 105–6	X-linked diseases 13, 133	
Turner syndrome 104–5, 109–10,	PGD 164–5, 191	
147	<i>see also</i> fragile X syndrome	zona pellucida breaching in PGD 159,
inactivation 105, 106	XPF (DNA repair enzyme)	160
	89	zygote 45, 56–7